ClinicalTrials.gg
Not yet recruitingNCT07049458Updated Oct 22, 2026

Study of CHO-A04 in Advanced Solid Tumors

A Phase 1/2 interventional study of CHO-A04 in Advanced Solid Tumors, sponsored by Cho Pharma Inc.. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Cho Pharma Inc. · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 22, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if the study drug, CHO-A04, works to treat solid cancers in adults. It will also aim to learn about the safety of CHO-A04 and find the best dose to use in future cancer treatment. The main questions it aims to answer are:

  • Which dose of CHO-A04 shows the best anti-cancer ability?
  • How will your body respond to CHO-A04 treatment?
  • How long will CHO-A04 remain in your body?

There are two stages of investigation in this study:

  • Phase I: to find the best anti-cancer dose of CHO-A04
  • Phase IIa: to find the CHO-A04 anti-cancer ability in specific cancer types

In this study, each participant will be assigned to one of the CHO-A04 dose levels. Participants will have CHO-A04 infusion via blood vessel once every week for four weeks. The CHO-A04 treatment may continue based on participants' condition and CHO-A04 safety evaluations.

Read the detailed description

This Phase I/IIa, open-label, dose-escalation and cohort-expansion study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of CHO-A04 in subjects aged ≥ 18 years with advanced solid tumors.

Both Phases I and Phase IIa include a screening period of up to 4 weeks and study treatment once every week starting from Cycle 1 Day 1 (C1D1) until any treatment discontinuation criterion is met. Each treatment cycle of the study treatment is 28 days.

Subjects will receive intravenous (IV) infusion of CHO-A04 once a week for 4 weeks (D1, D8, D15, D22) as a treatment cycle. After the completion of last dose of the study treatment, subjects should complete the end-of-treatment (EOT) visit, safety follow-up (EOS) visit, and survival follow-up visits, unless withdrawn from this study.

- Phase I (accelerated titration and traditional 3+3 dose-escalation): Phase I consists of the accelerated titration and the traditional 3+3 dose-escalation design. Eligible subjects will be sequentially assigned into one of the dose levels. Dose level will be escalated from dose level 1 (starting dose) at 1 mg/kg/week to dose level 5 at 12 mg/kg/week of CHO-A04 (or may be de-escalated to dose level -1 at 0.5 mg/kg/week). If any ≥ Grade 2 CHO-A04 related adverse events (AEs) occurs in dose level 1 or dose level 2 subjects, the dose escalation/de-escalation rule will follow the 3+3 design. Intra-subject dose-escalation is not allowed in this study.

- Phase IIa (cohort-expansion): Two cohorts of up to 10 subjects per cohort will receive the Recommend Phase 2 Dose (R2PD), which is a dose equal to or lower than MTD based on the SRC's decision. The Sponsor will determine the cancer type for each cohort before initiation of Phase IIa.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Advanced solid tumor
  • Anti-SSEA-4 antibody
  • Monoclonal antibody
  • Dose-escalation
03

In context

Lead sponsor

Cho Pharma Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. With either gender aged ≥ 18 years
  2. Histologically/ confirmed, locally advanced unresectable or solid tumors
  3. Must have been treated with established standard-of-care therapy, or physicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy
  4. Availability of specimens for SSEA-4 immunohistochemistry (IHC) staining (optional for Phase I). Acceptable tumor tissues include:

    1. Tumor tissue sample collected at the time of initial diagnosis
    2. The most recent available recurrent/metastatic tumor biopsy tissue is preferred if available (a pre-treatment biopsy is encouraged if the biopsy site is safely accessible) Note: This criterion is fulfilled if there is a qualified tumor sample (tumor cells were presented in the tumor biopsy tissue) and the tumor tissue slides can be obtained for IHC staining. It is not violated even if the staining result obtained after the screening visit reveals that the slides contain no identifiable tumor cells.
  5. Has at least one according to (RECIST) version 1.1
  6. (ECOG) performance score ≤ 2
  7. Has a of at least 12 weeks in the opinion of the Investigator
  8. Has adequate hematopoietic function:

    1. (ANC) ≥ 1500 cells/μL without the need of myeloid growth factor support within 1 week
    2. ≥ 90×103 counts/μL without the need of platelet transfusion support within 1 week
    3. ≥ 9.0 g/dL without the need of red blood cell (RBC) transfusion within 1 week
  9. Has adequate coagulation function: (INR) and activated partial thromboplastin time (APTT) ≤ 1.5× (ULN)
  10. Has adequate liver function:

    1. Total ≤ 1.5× ULN and no signs of jaundice (≤ 3× ULN for subjects with known Gilbert disease)
    2. (ALT) and aspartate aminotransferase (AST) ≤ 2.5× ULN or ≤ 5.0× ULN in case of documented hepatic metastasis or hepatocellular carcinoma (HCC). For subjects with HCC, the score must be ≤ 6
  11. Has adequate renal function: estimated (eGFR) ≥ 60 mL/min/1.73 m2) Note: eGFR (mL/min/1.73 m2) = 186.3 × (serum creatinine in mg/dL)-1.154 × (age)-0.203× (0.742 if female) × (1.212 if African American/black)
  12. Willingness and ability to comply with protocol-stated requirements, instructions, and restrictions per Investigator's judgment
  13. Is able to understand the nature of this clinical study and accepts to enter the study by signing the form (ICF)

Exclusion criteria

Exclusion Criteria:

  1. Has unresolved toxicities from prior anticancer therapy, defined as having not resolved to ≤ Grade 1 ( v5.0), except for alopecia and laboratory values listed in the inclusion criteria
  2. Has signs or symptoms of end-stage organ failure, major chronic illnesses other than cancer(s), or any severe concomitant conditions which, in the Investigator's opinion, make it undesirable for the subject to participate in the study, or could jeopardize compliance with the protocol
  3. History of another primary within the last 3 years (except for treated basal or squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, or in situ cancer of the cervix) prior to the planned first infusion
  4. Has any significant cardiovascular or pulmonary diseases, including:

    1. Poorly controlled hypertension (systolic blood pressure ≥ 160 mm Hg and diastolic blood pressure ≥ 100 mm Hg)
    2. (LVEF) \< 50% at the screening visit
    3. Congestive heart failure (defined as Class III or IV), myocarditis, myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, or coronary artery bypass graft within 24 weeks prior to the planned first infusion
    4. Uncontrolled serious cardiac arrhythmias, such as ongoing ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes) Note: Sustained ventricular tachycardia is defined as tachycardia that continues for more than 30 seconds or leads to hemodynamic compromise within 30 seconds and requires intervention
    5. interval (QTcF) > 480 ms demonstrated by at least two 12-lead ECGs > 30 minutes apart
    6. Evidence of active pneumonitis (including drug-induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or history of idiopathic pulmonary fibrosis. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
    7. History of 2nd or 3rd-degree atrioventricular conduction defects
  5. History of thromboembolic or cerebrovascular events within the last 24 weeks before the screening visit, including , cerebrovascular accident, or deep vein thrombosis
  6. Has other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would make the subject inappropriate for enrollment in this study in the opinion of the Investigator
  7. Has received anti-cancer therapies such as surgery on target lesions, chemotherapy, small molecule agent(s), hormone therapy, radiation therapy (except for palliative radiotherapy for bone of non-skeletal tumors), or any other anti-cancer agent(s) within 4 weeks or 5 half-lives of the treated agents, whichever is longer, prior to the first dosing. Has received prior anti-cancer monoclonal antibody therapy within 8 weeks prior to the first infusion.
  8. Has received systemic medication(s) (including, but not limited to, , cyclophosphamide, azathioprine, methotrexate, thalidomide, tumor necrosis factor-ɑ antagonists, and calcineurin inhibitors) within 2 weeks (for those with a half-life ≤ 72 hours) or 4 weeks (for those half-life > 72 hours) prior to study dosing.

    Note: For regular steroid use, ≤ 10 mg of prednisolone per day or equivalent is allowed. Inhaled or topical corticosteroids are allowed.

  9. Has participated in other clinical studies for product(s) or medical device within 4 weeks or 5 half-lives (if known) prior to the planned first infusion, whichever is longer
  10. Has received cell therapy within 12 weeks prior to the planned first infusion
  11. Prior allogeneic hematopoietic stem cell, solid organ, or bone marrow transplantation(s)
  12. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

    Note: Subjects with previously treated may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the planned first infusion and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases. This exception does not include carcinomatous meningitis which is excluded regardless of its clinical stability

  13. Has symptomatic or poorly controlled pleural effusion, pericardial effusion, or ascites
  14. With the following infections:

    1. History of active pulmonary tuberculosis infection ≤ 48 weeks prior to the planned first infusion, regardless of tuberculosis treatment
    2. Any major episode of infection requiring treatment with systemic antibiotics or hospitalization within 4 weeks prior to the planned first infusion
    3. Positive ; subjects with positive HBsAg test results can be considered as eligible if subjects can receive anti-HBV viral treatment(s), e.g., entecavir or tenofovir
    4. Positive anti-; subjects with positive for anti-HCV but with negative results for HCV viremia as shown by PCR are considered as eligible.
    5. Medical history showing confirmed -1 positivity
  15. Administration of a live, attenuated vaccine within 4 weeks prior to the planned first infusion or anticipation that such a live, attenuated vaccine will be required during the treatment period.
  16. With known or suspected to any ingredients of investigational product
  17. History of severe allergic, anaphylactic, or other severe hypersensitivity reactions to therapeutic humanized antibodies
  18. Female subject who is breastfeeding, has a positive pregnancy test result at eligibility checking, or expecting to conceive or have children within the projected duration of the trial, starting from the screening visit through 90 days after the last dose of study treatment.
  19. All male subjects and female subjects with * (between puberty and 2 years after menopause) refuse to use at least two of appropriate methods shown below from signing the ICF to at least 3 months after taking the last dose of study treatment.

    1. Use oral, injected, or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example, hormone vaginal ring or transdermal hormone contraception.
    2. Placement of an intrauterine device (IUD) or intrauterine system (IUS).
    3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.

      • Male or female subjects who have undergone the following procedures are considered without childbearing potential.

        • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 12 weeks before the screening visit. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
        • Male sterilization (24 weeks prior to the first infusion).
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Phase I Dose Level -1: 0.5 mg/kg/week

    Intravenous infusion weekly

    Drug: CHO-A04

  • Experimental
    Phase I Dose Level 1: 1 mg/kg/week [starting dose]

    Intravenous infusion weekly

    Drug: CHO-A04

  • Experimental
    Phase I Dose Level 2: 2 mg/kg/week

    Intravenous infusion weekly

    Drug: CHO-A04

  • Experimental
    Phase I Dose Level 3: 4 mg/kg/week

    Intravenous infusion weekly

    Drug: CHO-A04

  • Experimental
    Phase I Dose Level 4: 8 mg/kg/week

    Intravenous infusion weekly

    Drug: CHO-A04

  • Experimental
    Phase I Dose Level 5: 12 mg/kg/week

    Intravenous infusion weekly

    Drug: CHO-A04

  • Experimental
    Phase IIa: RP2D for Cancer type A

    Recommended Phase II dose (RP2D) level will be decided by Scientific Review Committee (SRC) based on accumulated study data in Phase I. Cancer type of each cohort will be determined before initiation of Phase IIa

    Drug: CHO-A04

  • Experimental
    Phase IIa: RP2D for Cancer type B

    Recommended Phase II dose (RP2D) level will be decided by Scientific Review Committee (SRC) based on accumulated study data in Phase I. Cancer type of each cohort will be determined before initiation of Phase IIa

    Drug: CHO-A04

Interventions

  • DrugCHO-A04

    CHO-A04 will be given intravenously (IV) once weekly for 4 weeks as a treatment cycle.

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with dose-limiting toxicity (DLT)

    DLT is evaluated based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.The 5 general grades includes Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening or disabling, and Grade 5: Death.

    Time frame: Up to 28 days after first dose (Cycle 1)

  2. Percentage of subjects occur with adverse events (AEs)

    Percentage of subjects with treatment-emergent adverse events (TEAEs), treatment-related adverse event (TRAEs), serious adverse events (SAEs), and infusion-related reactions (IRRs) will be measured. Severity grading will be assessed by the investigator based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. The 5 general grades includes Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening or disabling, and Grade 5: Death.

    Time frame: Up to 30 days after the last dose

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) is defined as the time from the date of initial dosing until the first date of either disease progression or death due to any cause.

    Time frame: From first dose to disease progression or death, whichever occurs first, assessed up to 12 months

  2. Overall response rate (ORR)

    ORR will be calculated by combining subjects with complete response (CR) or partial response (PR) based on RECIST v1.1 criteria in best response.

    Time frame: CT assessment every 2 cycles throughout the study till EOT follow-up

  3. Disease control rate (DCR)

    DCR is defined as the percentage of subjects with at least one complete response (CR), partial response (PR) or stable disease (SD) per RECIST v1.1.

    Time frame: From first dose to confirmed disease progression, assessed up to 12 months

  4. Duration of response (DOR)

    DOR is defined as time from the date of the first documentation of partial response (PR) or complete response (CR) per RECIST v1.1 to the date of progression

    Time frame: From date of first documented response (CR or PR) to date of disease progression or death, assessed up to 12 months

  5. Change in Eastern Cooperative Oncology Group (ECOG) performance score from baseline

    ECOG performance status is a scale used to assess how the disease affects the daily living abilities, and determine appropriate treatment and prognosis. It is a simple measure of functional status that determines ability of patient to tolerate therapies in cancer. The grading ranges from 0 (fully active, without performance restriction) to 5 (dead).

    Time frame: Throughout the study till 4 weeks after the last dose

  6. Blood Concentration of CHO-A04

    The concentration of CHO-A04 in blood

    Time frame: From day 1 pre-dosing, various time point after dosing and throughout the study till EOT follow-up (assessed up to 12 months)

  7. Anti-drug antibodies (ADAs) concentration

    The concentration of ADA in the blood

    Time frame: Baseline, various time point during treatment period, and EOT follow-up (assessed up to 12 months)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jul 2027; primary completion for Dec 2028, 17 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Dec 2025 → Jul 2027, primary completion Oct 2027 → Dec 2028 and completion Oct 2028 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jul 3, 2025
StartEst.
Jul 1, 2027was Dec 2025
Primary completionEst.
Dec 1, 2028was Oct 2027
CompletionEst.
Jul 1, 2029was Oct 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 1, 2025→Jul 1, 2027
Oct 22, 2026
Primary completion
Oct 1, 2027→Dec 1, 2028
Oct 22, 2026
Study completion
Oct 1, 2028→Jul 1, 2029
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Dec 1, 2025→Jul 1, 2027
    Primary completion Oct 1, 2027→Dec 1, 2028
    Study completion Oct 1, 2028→Jul 1, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07049458
Lead sponsor
Cho Pharma Inc.
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Jul 1, 2027 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

Tanny Tsao
Contact
tanny.tsao@chopharma.com.tw
+886-2-2655-8059
Chia-Chi (Josh) Lin, M.D., PhD.
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion